Logo

Leadiant Biosciences Revcovi's (elapegademase-lvlr) Receives FDA Approval for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID) in Pediatric and Adult Patients

Share this

Leadiant Biosciences Revcovi's (elapegademase-lvlr) Receives FDA Approval for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID) in Pediatric and Adult Patients

Shots:

  • The approval is based on two study results assessing Revcovi in patients and demonstrated in an increase in ADA activity- reduction in concentration of toxic metabolites with an improvement in total lymphocyte counts
  • Leadiant Biosciences’ Revcovi has received FDA’s Fast Track- Priority Review & ODD designation on 7 Jun- 2017- 27 Jun- 2018 & 19 Mar- 2015 respectively
  • Revcovi (elapegademase-lvlr) is a recombinant adenosine deaminase enzyme replacement therapy (ERT) indicated for ADA-SCID in pediatric and adult patients

Ref: Leadiant Biosciences | Image: Glassdoor

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions